Approved in the E.U.
Pixantrone (PIXUVRI®) was granted conditional marketing approval in the E.U. in May 2012 as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphomas. The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.
PIXUVRI is not approved in the U.S.
Learn more about PIXUVRI.